{"id":90544,"date":"2016-12-03T01:15:06","date_gmt":"2016-12-03T01:15:06","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=90544"},"modified":"2016-12-03T01:15:06","modified_gmt":"2016-12-03T01:15:06","slug":"creative-biolabs-released-a-comprehensive-list-of-hiaffi-recombinant-antibodies-for-clinical-immunotherapy-research","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-released-a-comprehensive-list-of-hiaffi-recombinant-antibodies-for-clinical-immunotherapy-research_90544.html","title":{"rendered":"Creative Biolabs Released a Comprehensive List of Hi-Affi\u2122 Recombinant Antibodies for Clinical Immunotherapy Research"},"content":{"rendered":"
\"\"<\/a><\/div>\n
Creative Biolabs is pleased to release thousands of Hi-Affi\u2122 recombinant antibodies for clinical immunotherapy research. <\/div>\n

Creative Biolabs is a leading custom service provider with years of experience in antibody production<\/a> and engineering. It has developed multiple pipelines to extend its services to over 26 countries.<\/p>\n

Theses recombinant antibodies are developed with its library construction and screening processes utilizing hybridoma and phage display technology.<\/p>\n

Recombinant antibody<\/a> is an antibody made through the use of recombinant DNA technologies by inserting a fragment of DNA into bacterium, yeast, and mammalian cells. Unlike traditional hybridoma based technologies, the rAbs can be expressed in an in vitro<\/em> environment. The recombinant antibodies produced in an animal-free system are widely used in medical research.<\/p>\n

Recombinant antibody drugs have developed through mice monoclonal (McAb), human-mice chimeric antibody, humanized antibody<\/a> and full human antibody. They have been applied in clinical immunotherapy for the treatment of cancer, autoimmune diseases, viral diseases, Alzheimer disease and other diseases.<\/p>\n

“Based on our optimized library construction and screening processes with hybridoma and phage display technology”, said Dr. Monica Müller, scientific officer of Creative Biolabs, “we can guarantee successful isolation of clones in a short time with high affinity up to sub-nanomolar level.”<\/p>\n

Recombinant antibodies produced in an animal-free system are widely used in medical research as well as the preparation of pharmaceutical compounds in order to treat various diseases. However, the gap between the basic research and clinical application still need to be filled. That’s why Creative Biolabs is focusing so much on recombinant antibody production.<\/p>\n

About Creative Biolabs<\/strong><\/p>\n

Over the last 10 years, Creative Biolabs has becoming a leader of recombinant antibody (rAb) discovery and manufacturing, providing high quality service to customers in academia and industry fields all over the world. Its products range from antibody \/ peptide libraries, Biosimilar cell lines, Chimeric antigen receptor (CAR) products, antibody-drug conjugates (ADCs) to engineered antibodies.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs
Contact Person:<\/strong> Candy Swift
Email:<\/strong> marketing@creative-biolabs.com
Phone:<\/strong> 1-516-669-8109
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.creativebiolabs.net\/<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Creative Biolabs is pleased to release thousands of Hi-Affi\u2122 recombinant antibodies for clinical immunotherapy research. Creative Biolabs is a leading custom service provider with years of experience in antibody production and engineering. It has developed multiple pipelines to extend its … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-90544","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/90544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=90544"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/90544\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=90544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=90544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=90544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}